CLBIO: Revenue down, losses widened, but US launch and new projects drive future potential

About this update from Corline Biomedical Ab

Revenue and earnings declined as key projects entered clinical phases, but Corline is preparing for a US launch with Kardium and expanding into regenerative medicine. Cash position and financing are being closely managed. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Corline Biomedical Ab